Semaglutide Market Faces Slump as Excess Stock Hits Rs 100 Crore
The explosive growth seen in India’s obesity therapy market has hit a sudden roadblock, leaving wholesalers and stockists grappling with significant unsold inventory. After a massive surge driven by generic launches, the semaglutide market is now facing a cooling period that could impact pharmaceutical margins.
The Inventory Overhang: A Rs 100 Crore Challenge
Following a period of hyper-growth, the semaglutide therapy market has encountered a significant slowdown in May. Industry estimates suggest that excess stock within the trade channel has reached approximately Rs 100 crore. This glut has forced stockists and wholesalers into a defensive posture, with many now holding 50–60 days of inventory—well above the standard industry norm of 30–45 days.
Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), confirmed that channel partners have paused fresh procurement from pharmaceutical manufacturers. This freeze on new orders is a strategic move to allow existing stocks to liquidate before the market absorbs more supply.
From Hyper-Growth to Market Moderation
The current stagnation stands in stark contrast to the explosive performance witnessed in April. Following the patent expiry of semaglutide on March 20, the market saw a flood of affordable generic brands from major Indian pharmaceutical players, including Sun Pharma, Dr. Reddy’s, and Torrent Pharmaceuticals.
In April, the Rs 2,000-crore obesity therapy market experienced a massive month-on-month (m-o-m) surge, with value growth hitting 50% and volumes jumping by 88%. However, the momentum stalled in May; according to Pharmarack data, m-o-m value growth decelerated to just 6%, while unit growth slowed to 12%.
Regulatory Impact and Competitor Performance
Industry experts suggest that the moderation in sales may not be purely a supply-demand issue but could be linked to recent regulatory shifts. In April, government advisories and prescribing restrictions were introduced, stipulating that GLP-1 therapies should only be prescribed by qualified specialists. This move is expected to tighten the prescribing landscape for these weight-loss and diabetes management drugs.
Despite the semaglutide slowdown, Eli Lilly’s Mounjaro (tirzepatide) remains a dominant force in the segment. Mounjaro saw a 12% increase in sales, reaching Rs 136 crore in May. This performance contributed to the broader growth of India’s Rs 2.5 lakh crore organized pharma retail market, which grew by nearly 11% in May, largely driven by chronic therapies.
Key Takeaways
- Inventory Glut: Stockists are holding 50–60 days of semaglutide stock, creating an estimated Rs 100 crore inventory overhang in the trade channel.
- Growth Deceleration: After a massive 50% value surge in April following patent expiry, May saw month-on-month value growth drop sharply to 6%.
- Regulatory Headwinds: New guidelines requiring specialized prescriptions for GLP-1 therapies are believed to be contributing to the sudden cooling of the market.